High-frequency alloreactive T cells augment effector function of low-frequency CD8+ T-cell responses under CD28/CD154 blockade

Transplantation

Volumn 89, Issue 10, 2010, Pages 1208-1217

  Floyd, Tamara L ^a   Orr, Steven B ^a   Coley, Shana M ^a   Hanna, Samantha S ^a   Wagener, Maylene E ^a   Kirk, Allan D ^a   Larsen, Christian P ^a   Ford, Mandy L ^a  

^a Currently   (United States)

Author keywords

Costimulation; Precursor frequency; T lymphocyte; Tolerance; Transplantation

Indexed keywords

CD28 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MR 1; OVALBUMIN; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; EFFECTOR CELL; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; SKIN GRAFT; SKIN TRANSPLANTATION; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED STRAINS; OVALBUMIN; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TRANSCRIPTIONAL ACTIVATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 77952884001     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181df53dc     Document Type: Article

References (34)

1. Badovinac VP, Haring JS, Harty JT. Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection. Immunity 2007; 26: 827.
2. Wirth T, Harty JT. Initial TCR transgenic precursor frequency alters functional behaviour of CD8 T cells responding to acute infection. Adv Exp Med Biol 2009; 633: 71.
3. + T cell survival controlled by clonal abundance. Science 2006; 312: 114.
4. Blair DA, Lefrancois L. Increased competition for antigen during priming negatively impacts the generation of memory CD4 T cells. Proc Natl AcadSci USA 2007; 104: 15045.
5. + T cell lineage commitment. NatImmunol2005; 6: 793.
6. Suchin EJ, Langmuir PB, Palmer E, et al. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question. J Immunol 2001; 166: 973.
7. Lindahl KF, Wilson DB. Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors. J Exp Med 1977; 145: 508.
8. Blattman JN, Antia R, Sourdive DJ, et al. Estimating the precursor frequency of naive antigen-specific CD8 T cells. JExp Med 2002; 195:657.
9. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
10. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005; 174: 542.
11. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74:933.
12. Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection: Suppression of allograft rejection by blockade of the CD-gp39 pathway 1. Transplantation 1996; 61: 4.
13. Williams MA, Trambley J, Ha J, et al. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. JImmunol 2000; 165: 6849.
14. + T cells can trigger allograft rejection. J Immunol 2000; 165:1111.
15. Trambley J, Bingaman AW, Lin A, et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. J Clin Invest 1999; 104: 1715.
16. Guo Z, Meng L, Kim O, et al. CD8-T cell-mediated rejection of intestinal allografts is resistant to inhibition of the CD40/CD154 costimu-latory pathway. Transplantation 2001; 71: 1351.
17. + T cells. J Immunol 1999; 163: 2358.
18. Markees TG, Phillips NE, Gordon EJ, et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998; 101: 2446.
19. Ford ML, Koehn BH, Wagener ME, et al. Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med 2007; 204: 299.
20. + T cell-mediated CD28/CD154-independent rejection. J Immunol 2008; 180: 7203.
21. + T cells to transplanted tissue. J Immunol 2008; 181: 5313.
22. Ehst BD, Ingulli E, Jenkins MK. Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. Am J Transplant 2003; 3: 1355.
23. Merrick A, Diaz RM, O'Donnell D, et al. Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: Expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naive cytotoxic priming and anti-tumour therapy. Cancer Immunol Immunother 2008; 57: 897.
24. Har-Noy M, ZeiraM, Weiss L, et al. Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma. Leuk Res 2009; 33: 525.
25. Har-Noy M, Zeira M, Weiss L, et al. Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity. Leuk Res 2008; 32:1903.
26. Bevan MJ. High determinant density may explain the phenomenon of alloreactivity. Immunol Today 1984; 5: 128.
27. + cytotoxic T lymphocytes in association with a class I MHC protein. Cell 1992; 69: 989.
28. Felix NJ, Donermeyer DL, Horvath S, et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 2007; 8: 388.
29. Heath WR, Kane KP, Mescher MF, et al. Alloreactive T cells discriminate among a diverse set of endogenous peptides. Proc Natl Acad Sci USA 1991; 88: 5101.
30. Heath WR, Sherman LA. Cell-type-specific recognition of allogeneic cells by alloreactive cytotoxic T cells: A consequence of peptide-dependent al-lorecognition. Eur J Immunol 1991; 21: 153.
31. Obst R, Munz C, Stevanovic S, et al. Allo-and self-restricted cyto-toxic T lymphocytes against a peptide library: Evidence for a functionally diverse allorestricted T cell repertoire. Eur J Immunol 1998; 28: 2432.
32. Panina-Bordignon P, Corradin G, Roosnek E, et al. Recognition by class II alloreactive T cells of processed determinants from human serum proteins. Science 1991; 252: 1548.
33. Wucherpfennig KW, Allen PM, Celada F, et al. Polyspecificity of T cell and B cell receptor recognition. Semin Immunol 2007; 19: 216.
34. Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nat Rev Immunol 2007; 7: 942.